@entity151 ( @entity151 ) is highly sensitive to chemotherapy. Despite a dramatic initial response, however, most @entity1 relapse. Given the activity of @entity136 in @entity1149 ( @entity1149 ), and early clinical trials suggesting activity of @entity136 in chemo-naive @entity151 @entity1 , we conducted a phase II study to determine the efficacy and @entity137 of @entity136 in @entity151 @entity1 who have failed first-line chemotherapy. @entity136 1250 mg/m(2) was given intravenously on days 1 and 8, every 3 weeks. Eligibility criteria included prior treatment with only one chemotherapy regimen and Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. @entity1 with brain metastases were eligible. RESULTS: Between April 1998 and October 2001, 27 @entity1 were enrolled: 15 @entity1 with sensitive (S) disease (recurred>3 months after first-line chemotherapy) and 12 @entity1 with refractory (R) disease (failed<3 months after first-line chemotherapy). Median age was 61 (range 45-74). All @entity1 had received prior @entity902 -based therapy involving @entity2879 and either @entity900 or @entity3003 . There were one early @entity204 and two early withdrawals because of @entity137 . No responses were observed. Of 24 @entity1 who received at least two cycles of @entity136 , only three achieved stable disease after six cycles while 21 progressed. The median @entity1054 ( @entity1054 ) was 6 weeks in S group, 5.6 weeks in R group, and 6 weeks overall. After a minimum potential follow-up of almost 1 year for all @entity1 , the median survival was 8.8 months in S group, 4.2 months in R group, and 6.4 months for the whole group. One-year survival rate was 33.3% in S group, 16.7% in R group, and 25.4% for all @entity1 . Myelosuppression was the most commonly observed adverse effect, with grade 3/4 @entity1398 in 30%, and grade 3 @entity882 in 30%. One @entity1 (3.7%) developed @entity221 . @entity1576 and @entity204 , possibly related to @entity358 , was observed in one @entity1 (3.7%). CONCLUSION: monotherapy @entity136 as second-line agent has limited activity in previously treated @entity151 .

Phase II study of second-line XXXX in sensitive or @entity151 .

@entity1 :: ('9606', 'Species') :: ['patient', 'Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities', 'toxicity'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity221 :: ('MESH:D005334', 'Disease') :: ['neutropenic fever'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small cell lung cancer', 'NSCLC'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1054 :: ('MESH:D000377', 'Disease') :: ['time to progression', 'TTP'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary toxicity'] @entity1576 :: ('MESH:D012131', 'Disease') :: ['Respiratory failure'] @entity151 :: ('MESH:D055752', 'Disease') :: ['Small cell lung cancer', 'SCLC'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['Gemcitabine', 'gemcitabine']
@entity136 :: (MESH:C056507,Chemical) :: ['gemcitabine']
